NEW YORK (AP) – Teva has offered to buy Mylan for about $40.1 billion in cash and stock in a deal that would create a powerhouse of generic drug development.
If Teva manages to acquire Mylan under the offer announced Tuesday, it would help Teva secure a more dominant position as it would be taking Mylan off of a growing list of competitors. Teva would also get a competitive edge against rivals such as Sun Pharma, which itself consolidated for a more powerful position when it took a controlling stake of its rival Ranbaxy in 2014.
But Mylan already announced Friday as speculation was swirling about a possible Teva bid that it doubted that regulators would approve such a deal and said it is committed to its current strategy as a stand-alone company.
The Dutch company said anti-trust regulators probably wouldn’t approve a deal between Mylan and Teva because their businesses overlap in major ways. But it conceded that it would thoroughly examine an offer if it received one.
Teva remains undeterred. President and CEO Erez Vigodman said in a statement Tuesday that the Israeli company is confident that any regulatory requirements needed to complete the deal “will be met in a timely manner.”
